Dr. Chen Benkler currently serves as the CEO of BrainTrust Bio. Prior to this position she served as the Chief Scientific Officer of Above and Beyond NB LLC where she participated in the development of the technology that is now at the core of BrainTrust Bio. With the blessing of Above and Beyond’s management, Dr. Benkler initiated the formation of BrainTrust Bio as a company dedicated to the development of that technology into a superhighway into the central nervous system. She was promoted to the Chief Scientific Officer for Above and Beyond NB LLC after a short term as the Director of Neuromuscular Restoration for Above and Beyond NB LLC where she successfully launch the first ever Neuromuscular Restoration Program aimed at rebuilding neuromuscular function by replacement of the depleting spinal motor neurons and formation of new neuromuscular junctions. She has an extensive background in gene therapy and neuroscience, with a focus on innovative and translational research for neurodegenerative diseases. Dr. Benkler received her Ph.D. in Genetics and Biochemistry from Tel Aviv University in 2013 after receiving a MS.C. in Medical Sciences and a B.Sc in life science. Her work resulted in several patents and collaborations driving her to co-found the Gene Therapy Biotechnology Start-up Neurogen LTD and serve as its CSO (2012-2014). Prior to that she served in the Israeli Intelligence Core (2004-2006). Dr. Benkler received her Post-Doctoral training as a Fellow in the Department of Stem Cell and Regenerative Biology at Harvard University (2013-2017).
